This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
WEST LAFAYETTE, Ind., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the following upcoming investment conferences in February:
Leerink Swann 2013 Global Healthcare Conference – Wednesday, Feb. 13, at 8:00 a.m. EST. The conference will be held at the Waldorf Astoria in New York City.
2013 RBC Capital Markets' Global Healthcare Conference – Tuesday, Feb. 26, at 3:35 p.m. EST. The conference will be held at the New York Palace in New York City.
2013 Citi Global Health Care Conference – Wednesday, Feb. 27, at 1:30 p.m. EST. The conference will be held at the Hilton New York Hotel in New York City.
Webcast information can be accessed under "Events & Presentations" in the Investor Relations section of Endocyte's website at
www.endocyte.com . All webcasts will be archived shortly after each live event and a replay will be available on the Company's website for 90 days following the conference.
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.